PCSA Key Statistics, Chart & Performance
The current stock price of PCSA is 3.36 USD. In the past month the price decreased by -51.46%. In the past year, price decreased by -84.21%.
PCSA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About PCSA
Company Profile
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. The company is headquartered in Vero Beach, Florida and currently employs 10 full-time employees. The company went IPO on 2013-10-07. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.
Company Info
PROCESSA PHARMACEUTICALS INC
601 21St Street, Suite 300
Vero Beach FLORIDA 21076 US
CEO: David Young
Employees: 10
Phone: 14437763133
PROCESSA PHARMACEUTICALS INC / PCSA FAQ
What does PCSA do?
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. The company is headquartered in Vero Beach, Florida and currently employs 10 full-time employees. The company went IPO on 2013-10-07. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.
Can you provide the latest stock price for PROCESSA PHARMACEUTICALS INC?
The current stock price of PCSA is 3.36 USD. The price decreased by -2.89% in the last trading session.
Does PROCESSA PHARMACEUTICALS INC pay dividends?
PCSA does not pay a dividend.
What is the ChartMill rating of PROCESSA PHARMACEUTICALS INC stock?
PCSA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is PROCESSA PHARMACEUTICALS INC (PCSA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PCSA.
Can you provide the market cap for PROCESSA PHARMACEUTICALS INC?
PROCESSA PHARMACEUTICALS INC (PCSA) has a market capitalization of 190.31M USD. This makes PCSA a Micro Cap stock.
PCSA Technical Analysis
PCSA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PCSA. While PCSA has a great health rating, there are worries on its profitability.
PCSA Financial Highlights
Over the last trailing twelve months PCSA reported a non-GAAP Earnings per Share(EPS) of -34. The EPS increased by 71.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -170.52% | ||
| ROE | -221.71% | ||
| Debt/Equity | 0 |
PCSA Forecast & Estimates
8 analysts have analysed PCSA and the average price target is 25.5 USD. This implies a price increase of 658.93% is expected in the next year compared to the current price of 3.36.